स्लोवाकिया -
स्लोवाक -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
thé salvat
leros spol.s r.o., Česká republika - iné liečivá - 94 - fytopharmaca
स्लोवाकिया -
स्लोवाक -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
stomaran
leros spol.s r.o., Česká republika - iné liečivá - 94 - fytopharmaca
स्लोवाकिया -
स्लोवाक -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
herbadent
herbadent s.r.o., Česká republika - iné liečivá - 94 - fytopharmaca
यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
zytiga
janssen-cilag international n.v. - abiraterón acetátu - prostatické nádory - endokrinná terapia - zytiga je uvedená s prednizónom alebo prednisolone na:liečbu metastatickým kastrácia odolný proti rakovine prostaty u dospelých mužov, ktorí sú bez príznakov alebo mierne symptomatických po poruche androgén deprivácie terapia, pri ktorej chemoterapia nie je zatiaľ klinicky indicatedthe liečbu metastatickým kastrácia odolný proti rakovine prostaty u dospelých mužov, ktorých choroba pokročila na alebo po docetaxel založené chemoterapia režim.
यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
abiraterone accord
accord healthcare s.l.u. - abiraterón acetátu - prostatické nádory - endokrinná terapia - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
abiraterone mylan
mylan ireland limited - abiraterón acetátu - prostatické nádory - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
abiraterone krka
krka, d.d., novo mesto - abiraterón acetátu - prostatické nádory - endokrinná terapia - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.